The Fly

Neximmune reports Q3 EPS (60c), consensus (69c)

"While we remain confident in the potential therapeutic benefit of our AIM ACT cell therapy programs, following a strategic review of our pipeline, indications, timelines and cash position, we have decided that the best path forward for NexImmune is to realign internal resources to focus on advancing our AIM INJ ‘off-the-shelf’ platform," said Kristi Jones, CEO. "We believe that the AIM INJ therapeutic modality offers the most disruptive potential to benefit patients, as well as the greatest potential to create long-term value for our shareholders. We believe there is a high level of excitement and momentum around our AIM INJ platform and its ‘off-the-shelf’ applications. Internally and externally generated evidence show encouraging signals of preclinical activity in models of oncology and autoimmune disorders. We will provide an update on these programs and continue to focus our resources to demonstrate the potential of our AIM INJ ‘IND engine’ to enable a rapid path to clinical development."

Published first on TheFly

See the top stocks recommended by analysts >>

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More